Serial No.: 10/088,775 Filed: March 20, 2002

Page 9

Remarks

Claims 1-4, 7-12, and 14-35 are pending and under examination in the subject application. Applicants have hereinabove amended claims 1, 2, 4, 7, 14, 15, and 17. Applicants maintain that the amendments to the claims raise no issue of new matter. Support for the amendments to claim 1 can be found in the specification as originally filed at, inter alia, page 12, lines 4-17; page 8, lines 2-3; and at page 31, lines 7-8. Support for the amendments to claim 2 can be found in the specification as originally filed at, inter alia, page 13, line 25 to page 14, line 18; and at page 31, lines 7-8. Support for the amendments to claim 4 can be found in the specification as originally filed at, inter alia, page 14, lines 23-27. Support for the amendments to claim 7 can be found in the specification as originally filed at, inter alia, page 5, line 31 to page 7, line 10; and page 8, lines 2-3. Support for the amendments to claims 14, 15, and 17 can be found in the specification as originally filed at, inter alia, page 18, lines 1-7. Accordingly, applicants respectfully request entry of this Amendment. After entry of this Amendment, claims 1-4, 7-12, and 14-35 will be pending and under examination.

Claims Rejected Under 35 U.S.C. §112 (First Paragraph)

In the October 19, 2004 Office Action, the Examiner stated that claims 1-4, 7-12, 14, 15, and 17-35 are rejected under 35 U.S.C. §112, first paragraph, for both written description and enablement.

In response, applicants respectfully traverse the Examiner's rejection. Applicants note that the recited calcium salt forms of gangliosides were chosen for coating solid particles because free acid gangliosides were found to clump. In addition, the materials

Serial No.: 10/088,775 Filed: March 20, 2002

Page 10

and methods section on page 31 of the specification clearly describes that calcium salt forms of the gangliosides were used. As such, applicants maintain that the calcium salt recitation in the claims is an actual exemplified embodiment, and that it is not new matter. Moreover, applicants maintain that the recited characteristic is explicitly described and clearly enabled in the specification as filed. Accordingly, respectfully request that the Examiner reconsider and withdraw this ground of rejection.

Claims Rejected Under 35 U.S.C. §103(a)

The Examiner stated that claims 1-3, 10, 13, 14, and 17-19 are rejected under 35 U.S.C. §103(a) as being unpatentable over Uhlig et al. (Autoimmunity 5:87-89, 1989) in view of Dwyer et al., Uemura et al., Ravindranaths et al., Pestronk et al., and in Beltz et al. as previously cited.

In response, applicants respectfully traverse the Examiner's rejection. Specifically, applicants note that "Ca++ salts" of gangliosides as recited in the claimed invention and employed by the applicants, are not explicitly taught by Uhlig et al. Furthermore, the assumption that the Type II ganglioside used by Uhlig et al. is a calcium salt is not supported in light of the fact that commercially available free acid gangliosides are also available (e.g. see Sigma catalogue page 918, Exhibit A, annexed hereto), especially in the absence of any mention by Uhlig et al. of ganglioside salt or Ca++ salt.

Furthermore, Uhlig et al. in combination with the other cited references do not teach passive adsorption of a Ca⁺⁺ salt of the ganglioside to at least two separate solid particles, as recited in the claims. At most, Uhlig et al. discuss a liposome made from lipids including gangliosides (see page 94-95 of Uhlig et al. and

Serial No.: 10/088,775 Filed: March 20, 2002

Page 11

page 91, "liposome preparation"), i.e. the ganglioside is a constituent of the liposome itself. The ganglioside is not a calcium salt form passively adsorbed onto the solid particle. The remaining cited references, in combination with Uhlig et al., do not cure this deficiency.

Moreover, Uhlig et al. in combination with the other cited references do not teach or suggest "contacting a liquid sample from the subject with the GM1, GM2, GM3, GD1, GD2, GD3, GD1a, GD1b, GT1b or GQ1b ganglioside, the ganglioside being affixed by passive adsorption of a Ca⁺⁺ salt of the ganglioside to at least two separate solid particles" as recited in the claims.

In addition, in regard to claim 2, Uhlig et al. in combination with the other cited references do not teach or suggest a method comprising exposing a liquid sample to two different gangliosides, each affixed by passive adsorption of a Ca⁺⁺ salt to at least two separate solid particles.

Accordingly, applicants maintain that the rejected claims define an invention not obvious from the cited references, and therefore respectfully request that the Examiner reconsider and withdraw this ground of rejection.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Serial No.: 10/088,775 Filed: March 20, 2002

Page 12

No fee, apart from the enclosed \$60.00 fee for a one month extension of time, is deemed necessary in connection with the filing of this Amendment. If any such fee is required, however, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


ohn P. White

Registration No. 28,678

Registration No. 28,678 Attorney for Applicants Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400



Applicant: Norman Latov et al. U.S. Serial No.: 10/088,775 Filed: September 16, 2002 Exhibit A

US \$

of Products

		21.	20 45-24 36 36 34 42 54
	(Cantinuation of	1	Gardnerella vaginalis selective sup- 1 vial 28
	(Continuation of) Gancidovir	G 453	9 plement
	homologous recombination of a gong of interest is	(Herc	Composition: (per vial)
	homologous recombination of a gene of interest is required.	WET ICE	
	Color white		Nalidixic acid: 15.00 mg Amphotericin B: 1.00 mg
	ε _{256 nm} 1 mM		An antibiotic supplement recommended for the
	Salubility 0.1 N HCl		selective isolation of Gardnerella vaginalis.
	Ref.: 1. Sprung, C.N., et al., Chromosome healing in mouse		Sufficient for 500 ml medium
	embryonic stem cells. Proc. Natl. Acad. Sci. USA 96, 6781-6786 (1999)	·	R: 61-20/21-36/38-42/43 S: 53-22-45-36/37/39
	2. Halloran, P.J., and Fenton, R.G., Irreversible G2-M arrest and		
,	cytoskeletal reorganization induced by cytotoxic nucleoside	1	y.
	analogues Cancer Res. 58, 3855-3865 (1998) 3. Rubsam, L.Z., et al., Cytotoxicity and accumulation of	l	
	ganciclovir triphosphate in bystander cells cocultured with		Gassner lactose agar 500 g 66
	herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59, 675 (1999)	G 943	
	4. Oon, C.J., et al., Hepatitis B virus variants with lamivudine-		Meat peptone, 7.00
	related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res.		Sodium chloride, 5.00 Lactose, 50.00
	41, 113-118 (1999)	1	Metachrome yellow, 1.25
	5. Cannon, J.S., et al., Human herpesvirus 8-encoded		Water blue, 0.625
	thymidine kinase and phosphotransferase homologues confer- sensitivity to gancidovir. J. Virol. 73, 4786–4793 (1999)		Agar, 13.00
	Yamasaki, H., et al., Role of connexin (gap junction) genes in		Used for detection and isolation of pathogenic
	cell growth control and carcinogenesis. C.R. Acad. Sci. # 322, 151-159 (1999)		Enterobacteriaceae. Ref.: Gassner, G., Centralbi, F. Bakt, I. Orig. 80, 219 (1918)
	R: 46-60-61 S: 53-45-36/37/39		Y
	Sanglioside Goter distato See: Disialoganglioside Gote Page 725	1	, in the second
	Sanglioside G _{D1b} , disialo See: Disialoganglioside-G _{D1b} Page 725	1	
			County to billion and the second of the seco
	Sanglioside G _{M1} , asialo See: Asialoganglioside G _{M1} Page 223		Gastric Inhibitory Polypeptide Human See: Gastrointesing Peptides Page 921
	Sanglioside G _{M2} , monosialo See: Monosialoganglioside G _{M2} Page 1437		
	Sangliosides Purified 10 mg 59.20	l	· · · · · · · · · · · · · · · · · · ·
G 2375	from bovine brain 25 mg 108.90	l	
(-o-c)	Type til 100 mg 321.90	ŀ	Gastric Inhibitory Polypeptide Porcine See: Gastrointesine
	Gangliosides are major constituents		Peptides Page 921
	of neuronal cell membranes and endoplasmic reticu- lum; contain a sialated polysaccharide chain linked to		
	ceramide through a β-glycosidic linkage; for classifi-	l	:
	cation of gangliosides see Svennerholm, L., et al.		
	(eds.), Structure and Function of Gangliosides, New		
	York, Plenum, 1980. A family of glycosphingolipids isolated from bovine	M 529	Monoclonal Anti-Gastric Mucin 0.2 ml 67: 3 from mouse 0.5 ml 133:
	brain	350	Liquid, Ascites fluid, Clone 45M1
	N-acetylneuraminic acid approx. 20%	DRY ICE	Immunogen: mucin from human
	Ref.: 1. Itoh, et al., Prevention of the death of the rat axotomized hypoglossal nerve and promotion of its regenera-	•	ovarian cyst fluid
	tion by bovine brain gangliosides. Glycobiology 9, 1247-1252	l	The product recognizes the mucin epitope g local in the peptide core of gastric mucin (>1,000 kD)
	(1999) 2. Yamakawa, Reflections on biochemistry. Thus started	l	This epitope is completely destroyed by thiol redu
	ganglioside research Trends Biol. Sci. 13, 452-454 (1988)	l	tion (using mercaptoethanol) and partially lost
	ianglioside G _{T1b} See: Trisialoganglioside-G _{T1b} Page 2089		following trypsin proteolysis, but is stable upon
	iangliotetraosyl ceramide See: Asialoganglioside G _{M1} Page 223	ĺ	periodate oxidation. The antibody reacts with ethanol-fixed, cultured epithelial cells and ethanol
			formalin-fixed, paraffin-embedded tissue sections
	iangliotriosyl ceramide See: Asialoganglioside-G _{M2} Page 223		stains the surface gastric epithelium of normal hum gastrointestinal tract and reacts with fetal, pre
€333> N G 6666	Aonocional Anti-GAP1 ^{IP48P} 0.2 mL 194.95 from mouse	l	cancerous and cancerous colonic mucosa, but not
3800	approx. 2 mg/mL, Buffered aqu-		with normal colon. It may be used in immunobloth
DRY ICE	eous solution, Purified immunoglobulin, Clone		(non-reducing conditions), immunocytochemistry
•	GP-3		immunohistochemistry and immunoradiofixation
	Immunogen: recombinant human GAP ^{1IP48P}		Enzymatic pretreatment of formalin-fixed, paraffer embedded sections may enhance staining internal
	Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide	Į	Species reactivity: chicken, hedgehog, pig, rabbit, i
	Antigen mol wt approx. 100 kDa	•	rat, mouse, monkey, human
	Species reactivity: human	l	contains 15 mM sodium azide
	Application(s)		Application(s) Immunoblotting suitable using non-reducing conditions
· ·	Immunocytochemistry suitable indirect ELISA suitable		Immunohistochemistry (formalin-fixed, paraffin-embedde)
	Isotype IgG2b		sections) 1:200 using formalin-fixed, paraffin-embed
	Application(s)		sections of human stomach Immunocytochemistry
	Immunoblotting . 1-2 μg/mL using human platelets extract		sotype
G	AR-DM See: Glyceraldehyde 2. phocphate Dehydropenase		Ref.: 1. Bara. J. et al. J. Immunol Meth. 149, 105 (1998)

www.sig

Anti-Gastrin from rabb Liquid, Wi Immunoger ment (1-13 The antiser gastrin I by immunoass gastrin-con embedded duodenum Species rea contains 15 Application Radioimmu Immunohist sections) . . sections of h

Gastrointest

these peptides, found to be body. They are inv

Alytesin pGlu-Gly-A Ala-Val-Gly Thr⁶]-Bornt 2803 **37**C) [31078-12minimum Bombesin a the Europe gical activit Ref.: Anasta:

Arg-Arg-Gas 5 Human Arg-Arg-Le-Ala-Tyr-Gly [84424-84-Substrate 6 (6535 (653 Ref.: Baldwir 656 (1982)

> Big Gastrin I. HG-34; Hu Gly-Pro-Prc Gly-Pro-Trp. Trp-Met-As [60675-77-Storage for Storage for activity.
> Ref.: 1. Huss vesicular mor cells. J. Physic 2. Sawada, A expression (P processing. A

minimum Similar to (Sigma. Ref.: Bishop, gastrin precu terology 115

minimum Ref.: Bishop, deavage of t prohormone (1998)

Large

Ref.: 1. Bara, J., et al., J. Immunol, Meth. 149, 105 (1946) 2. Bara, J., et al., Int. J. Cancer 47, 304 (1991)

GAP-DH See: Glyceraldehyde-3-phosphate Dehydrogenase Page 1430

G

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:		
☐ BLACK BORDERS		
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES		
☐ FADED TEXT OR DRAWING		
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING		
☐ SKEWED/SLANTED IMAGES		
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS		
☐ GRAY SCALE DOCUMENTS		
☐ LINES OR MARKS ON ORIGINAL DOCUMENT		
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY		

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.